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Outcomes:
Composite of ischemic or hemorrhagic stroke (new, sudden focal neurologic deficit from a presumed cerebrovascular cause persisting > 24 h) or systemic embolism (abrupt vascular insufficiency with arterial occlusion in the absence of other mechanisms).
Main results
In the derivation cohort, the rate of stroke or systemic embolism was 4% at 2 years and reduced creatinine clearance was an independent risk factor. In the validation cohort, the discriminant power of the R 2 CHADS 2 score did not, however, differ from the CHADS 2 score (Table) , but the net risk reclassification index improved with the R 2 CHADS 2 score (17%, 95% CI 12 to 22).
Conclusion
In patients with nonvalvular atrial fibrillation, adding renal dysfunction to the CHADS 2 score did not improve prediction of stroke or systemic embolism. 
*

Commentary
The strengths of the study by Piccini and colleagues are the large derivation and validation cohorts. Although the main purpose of the study was to improve prediction in patients at low risk by CHADS 2 score, all patients in the derivation cohort received anticoagulation and only 11 had CHADS 2 scores of 0 or 1. Further, the discriminant ability (c-statistics) of the 2 scores did not differ.
Uncertainty exists about the efficacy of anticoagulation in patients with creatinine clearance < 30 mL/min and in patients on dialysis because they have not been included in randomized trials. Observational studies show that the benefit of anticoagulation is attenuated and not statistically significant in such patients (1) . Also, compared with patients with higher kidney function, these patients experience 2-to 5-fold increased risk for bleeding with anticoagulation (2). Using R 2 CHADS 2 , patients with creatinine clearance < 60 mL/min will score at least 2, putting them under consideration for anticoagulation. We recommend continued use of CHADS 2 to stratify risk until randomized trials of patients with atrial fibrillation and creatinine clearance < 30 mL/min are done.
